- Home
- EOI vs TNGX Comparison
EOI vs TNGX Comparison
Compare EOI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- TNGX
- Stock Information
- Founded
- EOI 2004
- TNGX 2014
- Country
- EOI United States
- TNGX United States
- Employees
- EOI N/A
- TNGX N/A
- Industry
- EOI Finance/Investors Services
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EOI Finance
- TNGX Health Care
- Exchange
- EOI Nasdaq
- TNGX Nasdaq
- Market Cap
- EOI 870.1M
- TNGX 723.2M
- IPO Year
- EOI N/A
- TNGX N/A
- Fundamental
- Price
- EOI $21.42
- TNGX $6.76
- Analyst Decision
- EOI
- TNGX Strong Buy
- Analyst Count
- EOI 0
- TNGX 6
- Target Price
- EOI N/A
- TNGX $10.00
- AVG Volume (30 Days)
- EOI 83.6K
- TNGX 1.4M
- Earning Date
- EOI 01-01-0001
- TNGX 08-05-2025
- Dividend Yield
- EOI 7.19%
- TNGX N/A
- EPS Growth
- EOI N/A
- TNGX N/A
- EPS
- EOI N/A
- TNGX N/A
- Revenue
- EOI N/A
- TNGX $24,296,000.00
- Revenue This Year
- EOI N/A
- TNGX $6.56
- Revenue Next Year
- EOI N/A
- TNGX N/A
- P/E Ratio
- EOI N/A
- TNGX N/A
- Revenue Growth
- EOI N/A
- TNGX N/A
- 52 Week Low
- EOI $14.36
- TNGX $1.03
- 52 Week High
- EOI $18.88
- TNGX $11.92
- Technical
- Relative Strength Index (RSI)
- EOI 63.12
- TNGX 53.54
- Support Level
- EOI $21.17
- TNGX $6.51
- Resistance Level
- EOI $21.32
- TNGX $7.05
- Average True Range (ATR)
- EOI 0.20
- TNGX 0.38
- MACD
- EOI 0.01
- TNGX -0.06
- Stochastic Oscillator
- EOI 98.18
- TNGX 37.86
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.